" Legal highs" -Toxicity in the clinical and medico-legal aspect as exemplified by suicide with bk-MBDB administration

Forensic Science International

Volumn 222, Issue 1-3, 2012, Pages

  Rojek, Sebastian ^a   Kłys, Małgorzata ^a   Strona, Marcin ^a   Maciów, Martyna ^a   Kula, Karol ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Bk MBDB; LC ESI MS MS; Postmortem

Indexed keywords

2 METHYLAMINO 1 (3,4 METHYLENEDIOXYPHENYL)BUTAN 1 ONE; ADRENALIN; AMIODARONE; ANTIDOTE; ATROPINE; BETACOL; CATHINONE; CENTRAL STIMULANT AGENT; DESIGNER DRUG; DIPYRONE; DOPAMINE; MIDAZOLAM; MORPHINE; PSYCHOTROPIC AGENT; RINGER LACTATE SOLUTION; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ACIDOSIS; ADULT; ARTERIAL PRESSURE; ARTICLE; ASYSTOLE; AUTOPSY; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; BODY TEMPERATURE; BRADYCARDIA; CARDIOVERSION; CASE REPORT; CHEMICAL COMPOSITION; CLINICAL ASSESSMENT; CLINICAL FEATURE; DEATH; DISORIENTATION; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; ELECTROCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; EUPHORIA; EXTRAVASATION; GASTROINTESTINAL HEMORRHAGE; HEALTH STATUS; HEART ARREST; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HISTOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPERSALIVATION; HYPERTHERMIA; INTERMITTENT MANDATORY VENTILATION; LENGTH OF STAY; LETHAL DOSE; LUNG EDEMA; MALE; MEDICAL DOCUMENTATION; MEDICOLEGAL ASPECT; MUSCLE TONE; PETECHIA; PHYSICAL EXAMINATION; PLEURA EFFUSION; POLAND; PRIORITY JOURNAL; PUNCTURE; PUPIL REFLEX; RESPIRATORY ARREST; RESPIRATORY TRACT HEMORRHAGE; RESUSCITATION; SEIZURE; SUICIDE; SYNCHRONIZED INTERMITTENT MANDATORY VENTILATION; TACHYCARDIA; TOXICITY TESTING; TOXICOLOGY;

EID: 84865655811     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2012.04.034     Document Type: Article

References (34)

1. Kała M. Drugs scene in Poland from a forensic toxicologist's view. Przeg. Lek. 2010, 67(8):594-597.
2. Ramsey J., Dargan P.I., Smylline M., Davies S., Button J., Holt D.W., Wood D.M. Buying " legal" recreational drugs does not mean that you are not breaking the law. QJM 2010, 103(10):777-783.
3. Vardakou I., Pistos C., Spiliopoulou Ch. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol. Lett. 2010, 197:157-162.
4. Vardakou I., Pistos C., Spiliopoulou Ch. Drugs for youth via Internet and the example of mephedrone. Toxicol. Lett. 2011, 201:191-195.
5. Lindigkeit R., Boehme A., Eiserloh I., Luebbecke M., Wiggermann M., Ernst L., Beuerle T. Spice: a never ending story?. Forensic Sci. Int. 2009, 191:58-63.
6. Klimaszyk D., Nawrocka K. Acute intoxications with " Legal Highs" and recreational drugs-challenges for toxicologists. Probl. Forensic Sci. 2009, 80:450-458.
7. Łukasik-Głebocka M., Sommrfeld L., Nawrocka K. Legal highs toxicity-symptomatology and clinical diagnosis in cases series. Przeg. Lek. 2010, 67(8):613-616.
8. Zaitsu K., Katagi M., Kamata H.T., Miki A., Tsuchihashi H. Discrimination and identification of regioisomeric b-keto analogues of 3,4-methylenedioxyamphetamines by gas chromatography-mass spectrometry. Forensic Toxicol. 2008, 51:26-45.
9. Reitzel L.A., Dalsgaard P.W., Müller I.B., Cornett C. Identification of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as a part of a police investigation of a Danish Internet company. Drug Test. Anal. 2011, Early view (online version of record published before inclusion in an issue). 10.1002/dta.358.
10. Uchiyama N., Kikura - Hanajiri R., Kawahara N., Goda Y. Analysis of designer drugs detected in the products purchased in fiscal year 2006. Yakugaku Zasshi 2008, 128(10):1499-1505.
11. Zuba D., Byrska B., Maciów M. Comparison of " herbal highs" composition. Anal. Bioanal. Chem. 2011, 400:119-126.
12. Takahashi M., Nagashima M., Suzuki J., Seto T., Yasuda I., Yoshida T.T. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography-mass spectrometry. Talanta 2009, 77(4):1245-1272.
13. Moffat A.C., Osselton M.D., Widdop B., Watts J. Clarke's Analysis of Drugs and Poisons 2011, Pharmaceutical Press, p. 180. Fourth ed.
14. Advisory Council on the Misuse of Drugs Consideration of the Cathinones, 31 March 2010, Advisory Council on the Misuse of Drugs, Home Office, London.
15. Kalix P., Brenneisen R., Koelbing U., Fisch H.U., Mathys K. Khat, a herbal drug with amphetamine properties. Schwiez. Med. Wochenschr. 1991, 121(45):1561-1566.
16. Kalix P. Cathinone, a natural amphetamine. Pharmacol. Toxicol. 1992, 70(2):77-86.
17. Karila L., Reynaud M. GHB and synthetic cathinones: clinical effects and potential cosequences. Drug Test. Anal. 2010, 3(9):552-559.
18. Dunkley E.J., Isbister G.K., Sibbritt D., Dawson A.H., Whyte I.M. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Aust. N. Z. J. Psychiatry 2007, 41(August (8)):649-655.
19. Silins E., Copeland J., Dillon P. Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. Aust. N. Z. J. Psychiatry 2007, 41(8):649-655.
20. Krasnova I.N., Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 2009, 60(May (2)):379-407.
21. Felgate H.E., Felgate P.D., James R.A., Sims D.N., Vozzo D.C. Recent paramethoxyamphetamine deaths. J. Anal. Toxicol. 1998, 22(March-April (2)):169-172.
22. G. Garrett, M. Sweeney, The serotonin syndrome as a result of mephedrone toxicity, Ann. Emerg. Med. 2012, BMJ Case Reports 2010, doi:10.1136/bcr.04.2010.2925.
23. Mugele J., Nañagas K.A., Tormoehlen L.M. Serotonin syndrome associated with MDPV use: a case report. QJM 2003, 96(September (9)):635-642.
24. Zaitsu K., Katagi M., Kamata T., Kamata H., Shima N., Tsuchihashi H., Hayashi T., Kuroki H., Matoba R. Determination of a newly encountered designer drug " p-methoxyethylamphetamine" and its metabolites in human urine and blood. Forensic Sci. Int. 2008, 177(May (1)):77-84.
25. Nicholson P.J., Quinn M.J., Dodd J.D. Headshop heartache: acute mephedrone 'meow' myocarditis. Heart 2010, 96(December (24)):2051-2052.
26. Staack R.F., Maurer H.H. Metabolism of designer drugs of abuse. Curr. Drug Metab. 2005, 6:259-274.
27. Zaitsu K., Katagi M., Kamata H.T., Kamata T., Shima N., Miki A., Tsuchihashi H., Mori Y. Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci. Int. 2009, 188:131-139.
28. Elliott S.P. MDMA and MDA concentrations in antemortem and postmortem specimens in fatalities following hospital admission. J. Anal. Toxicol. 2005, 29(July-August (5)):296-300.
29. De Letter E.A., Stove C.P., Lambert W.E., Piette M.H. Post-mortem (re)distribution of 3,4-methylenedioxymethamphetamine (MDMA, " ecstasy" ): human and animal data. Curr. Pharm. Biotechnol. 2010, 11(August (5)):453-459.
30. Pinorini-Godly M.T., Sporkert F., Schläpfer M., Rusconi M., Conti A. Intoxication with butylone and phenazepam among young cocaine users. Toxichem. Krimtech. 2010, 77(3):226-227.
31. Court record reg. No III K 107/11 - District Court in Poznań, Poland.
32. Hannak D., Scharbert F., Kattermann R. Stepwise binary gradient high-performance liquid chromatographic system for routine drug monitoring. J. Chromatogr. A 1996, 728(March (1-2)):307-310.
33. Reitzel L.A., Dalsgaard P.W., Müller I.B., Cornett C. Identification of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish Internet company. Drug Test. Anal. 2011, 10.1002/dta.358.
34. Bell C., George C., Kicman A.T., Traynor A. Development of a rapid LC-MS/MS method for direct urinalysis of designer drugs. Drug Test. Anal. 2011, 3(July-August (7-8)):496-504. 10.1002/dta.306.